Clinical Trial Update: Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing almonertinib to osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC | Phase 3 | Status: UNKNOWN